Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

ABSTRACT: The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. The researchers also want to learn about the side effects of the combination of drugs used in this study.

DISEASE(S): Adenocarcinoma,Carcinoma,Breast Neoplasms,Breast Cancer

PROVIDER: 2071265 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Clinical and molecular characterization of the cisplatin-vinorelbine chemotherapeutic regimen in HER2(-) metastatic breast cancer

Project description:Despite rapid advances in treatment options, challenges still persist in advanced breast cancer. Bevacizumab is a VEGF-neutralizing antibody with proven efficacy in combination with chemotherapy for treatment of HER2 negative metastatic breast cancer (mBC). Vinorelbine, a semisynthetic vinca alkaloid, is a well-established and well tolerated chemotherapeutic in breast cancer. The combination of vinorelbine with platinum and addition of bevacizumab is relatively underreported in the literature. We propose this combination regimen as safe, well tolerated and efficacious in HER2 negative mBC patients.

2024-05-16 | GSE267621 | GEO

Assessment of tumor pathological and transcriptional biomarkers in pre- and on-treatment core biopsies predictive of response and outcome after neoadjuvant chemotherapy plus Bevacizumab in patients with HER2-negative breast cancer

Project description:Assessment of tumor pathological and transcriptional biomarkers in pre- and on-treatment core biopsies predictive of response and outcome after neoadjuvant chemotherapy plus Bevacizumab in patients with HER2-negative breast cancer: Results from a multi-center, single-arm, phase 2 study (the PROMIX trial) Global gene expression profiling was performed on samples from 3 time points (baseline, after 2 cycles and surgery) from women with breast cancer receivcing neoadjuvant chemotherapy with bevacizumab in a phase 2 trial

2017-09-01 | GSE87455 | GEO

Changes in miRNA expression through the course of neaodjuvant Avastin in breast cancer

Project description:Molecular responses in breast cancer tumors after treatment with antiangiogenic therapy are largely unknown. In this experiment, we have assessed the efficacy of bevacizumab in HER2 negative breast carcinomas treated with a neoadjuvant chemotherapy regimen consisting of sequential anthracycline and taxane. miRNA expression profiles of the tumors before, during and after treatment are compared to shed light on changes in miRNA profile following therapy.

2020-01-01 | E-MTAB-7634 | biostudies-arrayexpress

Immuno-priming with bevacizumab: durvalumab plus bevacizumab after prolonged exposition to bevacizumab in breast cancer

Project description:Purpose: To study the potential priming benefit of bevacizumab from subsequent immunotherapy (durvalumab) in advanced breast cancer patients Methods: We tested this hypothesis by adding durvalumab after progression to maintenance single-agent bevacizumab treatment in advanced HER2-negative patients (average 3 treatment lines). In order to study the potential priming benefit, patients had to experience disease progression while on bevacizumab maintenance prior to entering the trial. In addition, we sought to find traits in peripheral-blood mononuclear cells (PBMCs) and tumor biopsies that informed about this immuno-priming, in an attempt to search for novel biomarkers of efficacy of the combo and obtain a better understanding of the biology of this clinical scenario. Results: Patients that experienced clinical benefit, compared with the remaining patients, displayed a lymphocyte pattern in PBMCs consisting on increased T-effector subpopulations (CD4- and CD8- effector and effector-memory) and decreased immunosuppressive T-regulatory cells. Gene-expression studies in tumor samples showed a congruent pattern, with increased T-effector and memory T cell signatures in responders, and increased T-regulatory and decreased active dendritic cells in non-responders. These events were observed in patients that displayed vascular normalization features as a result of previous bevacizumab, supporting the immuno-priming effects of this strategy.

2020-10-15 | GSE139050 | GEO

Expression data from breast cancer FNA biopsies from patients (US samples)

Project description:This is Phase II Trial of 4courses of 5-fluorouracil, doxorubicin and cyclophosphamide follwed by 4 additional courses of weekly docetaxel and capecitabine administered as Preoperative Therapy for Patients with Locally Advanced Breast Cancer, Stages II and III by US oncology (PROTOCOL 02-103) We performed gene set analysis (GSA) using functionally annotated gene sets corresponding to almost all known biological processes in ER-positive/HER2negative and ER-negative/HER2-negative breast cancer, respectively.

2011-02-07 | GSE23988 | GEO

Transcriptional profiling of human breast tumor samples before and after treatment with chemotherapy with and without bevacizumab.

Project description:Molecular responses in tumors after treatment with antiangiogenic therapy are largely unknown. In this experiment, we have assessed the efficacy of bevacizumab in HER2 negative breast carcinomas treated with a neoadjuvant chemotherapy regimen consisting of sequential anthracycline and taxane. Whole genome gene expression profiles of the tumors before, during and after treatment are compared to shed light on change in transcriptional profile following therapy.

2017-06-30 | E-MTAB-4439 | biostudies-arrayexpress

Small RNA-seq of breast tumor biopsies prior to treatment with letrozole or letrozole with bevacizumab

Project description:Biopsies were collected from post-menopausal women with ER+ HER2- breast cancer who were subsequently treated with either letrozole or letrozole plus bevacizumab.

2019-12-19 | GSE142308 | GEO

Pre-treatment expression data from neoadjuvant platinum & bevacizumab treated triple negative breast cancer patients

Project description:Gene expression data from 21 triple negative breast cancer samples treated with cisplatin & bevacizumab in the neoadjuvant setting as part of a clinical trial. Gene expression data RMA normalized was used to find predictors of platinum sensitivity

2018-02-19 | GSE103668 | GEO

Expression data from breast cancer FNA biopsies from patients (US samples)

2011-02-07 | E-GEOD-23988 | biostudies-arrayexpress

Transcriptome profiling of tumors from Caucasian and African American triple negative breast cancer (TNBC) patients.

Project description:Triple negative breast cancer is an aggressive phenotypic breast cancer characterized by ER negative, PR negative and Her2 negative immunohistochemistry status. We embarked on a study to explore the transcriptome of African American and Caucasian TNBC patients and identify race specific biomarkers.

2021-04-28 | GSE142731 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data